证券代码：300003 证券简称：乐普医疗 公告编号：2025-038 乐普（北京）医疗器械股份有限公司 2、会议主持人：董事长蒲忠杰先生 3、会议召开方式：本次股东大会采取现场投票及网络投票相结合的方式。 4、会议召开时间： 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会决议。 一、会议召开和出席情况 1、会议召集人：董事会 （1）现场会议召开日期和时间：2025 年 5 月 15 日下午 14:00。 （2）网络投票日期和时间：通过深圳证券交易所交易系统进行网络投票的 具体时间为2025年5月15日上午9：15－9：25、9：30-11：30，下午13：00-15： 00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年5月15日上午 9∶15 至下午15∶00。 5、现场会议召开地点：北京市昌平区超前路 37 号公司会议室 6、本次会议的召集、召开与表决程序符合法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 ...

最新一期业绩显示，2025年一季报，公司实现营业收入17.36亿元，同比-9.67%；净利润3.79亿元，同 比-21.44%，销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)110乐普医疗147.5985.831.38211.94亿行业平均 49.4645.354.63105.58亿行业中值36.1637.372.5047.48亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-597.76299.814.7963.00亿3诺唯赞-409.62-484.482.2587.66亿4爱朋医疗-360.69274.024.3429.60亿5博晖 创新-322.93512.443.4547.38亿6硕世生物-134.71-1968.471.2139.40亿7奥精医疗-119.67-175.401.5822.21亿 8睿昂基因-100.21-82.271.4212.97亿9康泰医学-86.02-72.673.0756.61亿10中红医疗-69.48-55.420.8848.28亿 11华大智造-62.11-55.114.28331.13亿 来源：金融界 从行业 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight decline of 0.23% recently, reflecting a mixed performance over different time frames, with a year-to-date decrease of 0.88% [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,568.19 points with a trading volume of 15.409 billion yuan [1]. - Over the past month, the index has increased by 2.13%, while it has decreased by 5.63% over the last three months [1]. - The index has a year-to-date decline of 0.88% [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.73%), Aier Eye Hospital (8.29%), and United Imaging Healthcare (7.73%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (61.00%) and the Shanghai Stock Exchange (39.00%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern Asset Management's various funds and Tianhong's ETF [2].

Core Viewpoint - The company is focusing on the development and commercialization of GLP-1 drugs and brain-computer interface technologies, while facing challenges in financial performance for 2024 and Q1 2025 [1][2]. Group 1: GLP-1 Drug Development - The company has completed Phase II clinical trials for its GLP-1/GCGR/GIP-Fc fusion protein MWN101 injection for obesity and type 2 diabetes, and is currently expanding the Phase II trials [1]. - The company aims to license overseas rights for MWN105 and MWN109 injections, both of which have received FDA clinical trial approval [1]. Group 2: Financial Performance - In 2024, the company reported total revenue of 6.103 billion yuan, a year-on-year decrease of 23.52%, and a net profit attributable to shareholders of 247 million yuan, down 80.37% [1]. - For Q1 2025, the company achieved revenue of 1.736 billion yuan, a year-on-year decline of 9.67%, with a net profit of 379 million yuan, down 21.44% [1]. Group 3: Future Growth Drivers - The company expects growth from the launch of core products for structural heart disease and peripheral interventional products, which are anticipated to increase sales as they enter the market [2]. - The company has plans for the commercialization of brain-computer interface products, with a focus on rehabilitation solutions for patients with neurological damage [2]. Group 4: Supply Chain and Market Impact - The company has limited reliance on single-source raw materials from the U.S. and has been promoting domestic alternatives for several years [3]. - The revenue from the U.S. market is projected to be less than 1% of total revenue in 2024, indicating minimal impact from U.S.-China tariff policies [3].

乐普医疗（300003）公告，公司第六届监事会主席王兴林先生因病医治无效于近日不幸逝世。王兴林先 生在担任监事会主席期间，恪尽职守、勤勉尽责，为公司发展所做的努力和贡献表示衷心感谢。王兴林 先生逝世后，公司监事会成员减少至2人，低于《公司法》和《公司章程》规定的最低人数，公司将尽 快完成监事的补选工作。 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-036 乐普（北京）医疗器械股份有限公司 关于子公司 MWN109 片获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称"公司"）于今日获悉，公 司控股子公司上海民为生物技术有限公司（以下简称"民为生物"）收到国家药 品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，由民为生物申 报的 MWN109 片临床试验申请获得批准，现将有关详情公告如下： 一、产品信息 药物名称：MWN109 片 注册分类：化学药品 1 类 申请事项：临床试验 申请人：上海民为生物技术有限公司 | 适应症 | 受理号 | | --- | --- | | 2 型糖尿病 | CXHL2500239、CXHL2500240、CXHL2500241、CXHL2500242 | | 超重或肥胖 | CXHL2500234、CXHL2500235、CXHL2500236、CXHL2500237 | 根据《中华人民共和国药品管理法》及有关规定，经审查， ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-035 董事会 乐普（北京）医疗器械股份有限公司（以下简称：公司）沉痛公告，公司第 六届监事会主席王兴林先生因病医治无效于近日不幸逝世。 公司董事、监事、高级管理人员及全体员工对王兴林先生的不幸逝世表示沉 痛哀悼和深切缅怀，并向其亲属致以深切的慰问！ 王兴林先生在担任公司监事会主席期间，恪尽职守、勤勉尽责，忠实地履行 了作为监事会主席应尽的职责和义务，在保障公司监事会合规决策、维护公司及 股东的整体利益等方面尽职尽责，为公司规范运作和高质量发展发挥了积极作用。 公司对王兴林先生为公司发展所做的努力和贡献表示衷心感谢！ 王兴林先生逝世后，公司监事会成员减少至 2 人，低于《公司法》和《公司 章程》规定的最低人数，公司将根据有关法律法规及《公司章程》的规定，尽快 完成监事的补选工作，并及时履行信息披露义务。 特此公告。 乐普（北京）医疗器械股份有限公司 乐普（北京）医疗器械股份有限公司 关于监事会主席逝世的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二○二五年五月九日 ...

Core Viewpoint - The new materials industry is rapidly growing and is considered a leading sector in the era of hard technology, with significant contributions to high-tech applications, traditional industry upgrades, and national defense capabilities [3][4]. Industry Trends - The global new materials market is expected to reach a scale of 5.6 trillion USD by 2025, with a compound annual growth rate (CAGR) of 13.3% from 2020 to 2025 [50]. - In China, the industry scale increased from 0.8 trillion CNY in 2010 to 8.2 trillion CNY in 2023, with a projected target of 10 trillion CNY by 2025 [13][50]. - The average annual growth rate of the new materials industry is over 15% [13]. Key Innovations - Breakthroughs in semiconductor materials have led to domestic alternatives, such as Huawei's 5G base station chips [8]. - Carbon fiber materials are crucial for the mass production of the C919 aircraft, enhancing autonomous high-end equipment manufacturing [10]. - The development of biodegradable medical coatings has facilitated the domestic production of joint prosthetics, with over 100,000 clinical uses reported [10]. Regional Development - The Yangtze River Delta has become a hub for magnetic materials, while the Pearl River Delta is nurturing new display materials [13]. - Jiangsu province accounts for 35% of the national high-performance fiber production, and Shanghai has a new materials R&D investment intensity of 4.2% [13]. - The western regions are experiencing rapid investment growth, with Sichuan's lithium battery materials investment increasing by 48% annually [15]. Talent Supply and Demand - The new materials industry is witnessing a significant influx of young, highly educated talent, with 44.86% of the workforce aged between 25-35 years [74]. - The demand for talent in the new materials sector is concentrated in the Yangtze River Delta and Pearl River Delta regions, which together account for over 40% of the total demand [86]. - By 2025, the total talent demand in the new materials industry is expected to reach 10 million, with a talent gap of 4 million [84]. Employment Trends - The industry is characterized by a high demand for R&D and technical positions, with material engineers and process engineers being the most sought-after roles [92]. - Private enterprises dominate the talent demand landscape, accounting for 63.5% of the total demand, reflecting the market-driven nature of the industry [90]. - The demand for cross-disciplinary talent is evident, with significant representation from mechanical, electrical, and chemical engineering backgrounds [81]. Market Dynamics - The new materials sector is experiencing a surge in capital investment, with a projected 40% increase in financing activities in 2024, exceeding 25 billion CNY [63]. - The industry is also seeing a trend towards localized supply chains, with companies like Ningde Times investing heavily in overseas production facilities [69][71]. - The competitive landscape is intensifying, with companies focusing on technological innovation and market expansion to capture growth opportunities [99].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, reflecting a mixed performance over different time frames [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.39% to 13,367.74 points, with a trading volume of 14.635 billion yuan [1]. - Over the past month, the index has increased by 5.82%, while it has decreased by 2.05% over the last three months and by 2.72% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include: Mindray Medical (9.57%), Aier Eye Hospital (8.34%), United Imaging (7.63%), Aimeike (3.55%), Huatai Medical (3.28%), Yuyue Medical (2.88%), New Industry (2.81%), Meinian Onehealth (2.35%), Lepu Medical (2.07%), and Jiuan Medical (2.03%) [1]. Group 3: Market Segmentation - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.66%) and the Shanghai Stock Exchange (39.34%) [1]. - In terms of industry composition, medical devices account for 34.34%, medical consumables for 27.26%, in vitro diagnostics for 21.50%, and medical services for 16.90% [2]. Group 4: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, C, and I, Tianhong China Securities Index Healthcare Equipment and Services ETF, and others [2].

Core Viewpoints - The segmented fields show differentiated growth: semiconductor materials grow at 50%, new energy materials at 52%, and biomedical materials at 87%, while traditional structural materials maintain a stable growth of 8-10% [2] - Emerging fields are rapidly rising: AI servers with high-frequency materials grow at 60%, new energy vehicles with MLCC at 100%, foldable screens with UTG glass at 30%, and hydrogen energy with a 60% localization rate for proton exchange membranes [2] - The industrial chain is changing: semiconductor materials are developed in a bundled manner with "wafer factories + material factories," while new energy materials involve a three-in-one integration of car manufacturers, battery factories, and material suppliers [2] Market Analysis - The Chinese innovative materials market has formed a diversified tiered structure, reaching a total scale of 6 trillion yuan in 2024, with a forecast to exceed 10 trillion yuan in 2025. The segmented fields show differentiated growth: semiconductor materials (50% growth), new energy materials (52%), and biomedical materials (87%) constitute three major growth poles, while traditional structural materials grow steadily at 8-10% [10][11] - The application field is being restructured, with traditional applications (aerospace, automotive manufacturing) dropping from 65% in 2019 to 48% in 2023, while emerging fields like AI servers (CCL usage growth of 60%), new energy vehicles (MLCC demand growth of 100%), and foldable screens (UTG glass demand growth of 30%) are rapidly rising [10] Competitive Landscape and Industrial Chain Evolution - The industry concentration is accelerating, showing a dual-track pattern of "national teams leading + private specialization." China National Building Material Group, as a representative of "national materials," has achieved breakthroughs in carbon fiber and silicon nitride ceramics, with R&D investment exceeding 10 billion yuan in 2023 [12] - The collaborative model in the industrial chain is innovating significantly. In the semiconductor materials field, a "wafer factory + material factory" bundled development model has formed, while new energy materials show a three-in-one R&D model involving car manufacturers, battery factories, and material suppliers [12] Future Market Space - The innovative materials market in China is expected to reach 10 trillion yuan by 2025 and exceed 30 trillion yuan by 2030, maintaining a CAGR of 18%. The growth engines come from deepening domestic substitution, technological iteration dividends, and the expansion of emerging applications [19] - Key areas to focus on include high-end photoresists, aerospace engine materials, solid-state batteries, high-temperature superconducting materials, perovskite photovoltaic materials, high-frequency materials, MLCC, UTG glass, silicon-carbon anodes, AI + new materials, and biodegradable materials [10][19] Policy Environment and Institutional Innovation - The national strategic layout provides strong support, with the Ministry of Industry and Information Technology clarifying key development directions for frontier materials, and local governments increasing support, such as Guangdong Province establishing a 10 billion yuan new materials industry fund [15] - The policy combination has shown significant effects, with the first application insurance compensation mechanism covering 80% of key materials, reducing R&D risks for enterprises by 30% [15] Technological Innovation and Industry Upgrade - The materials genome engineering is revolutionizing the R&D model, significantly shortening the development cycle of new materials [16] - Breakthroughs in production processes are reshaping cost curves, with significant reductions in unit costs and improvements in yield rates for various materials [16] Investment Strategy Recommendations - Focus on three major tracks: high-end semiconductor materials, new energy materials, and biomedical materials. Risk control should pay attention to technological route risks and the competitive landscape of leading enterprises [25][26] - The certainty of domestic substitution is high, with significant opportunities in solid-state electrolytes and superconducting materials [26]